Novo Nordisk (Ozempic)

9345.905 - 9372.085 David Rosenthal

So that's showing great promise. It was approved in the U.S. for diabetes treatment in May 2022, and approval just came recently in November 2023 for official FDA-sanctioned weight loss use case under the marketing name ZepBound. So look for that in 2024. What this really shows, though, between Eli Lilly and Novo and other companies that are almost certainly going to get into the GLP-1 business is